Immune Biosolutions has announced the publication of results from Phase 1 and 2 trials of the company’s IBIO123 inhaled antibody therapy in patients with COVID-19 in The Lancet Infectious Diseases. Immune Bio announced the initiation of the Phase 1 trial in October 2021.
According to the journal article, the Phase 2 study was stopped early because COVID-19 became less prevalent. The authors report that the study missed its primary endpoint of reduction in viral load; although the viral load reduction was greater in the treatment group than in the placebo group, the difference was not statistically significant. The company’s press release touts the results on a secondary endpoint where resolution of respiratory symptoms at Day 8 was 41% in the treatment group compared to 17% in the placebo group.
The company says that the results suggest that IBIO123 could be “particularly effective” against COVID-19 but that “Immune Biosolutions does not currently have the funding to produce the drug in sufficient quantities for Canada to be self-sufficient in the event of a new wave of COVID-19” and would still “have to take the necessary steps to obtain approvals and notices of compliance from the various government health authorities.”
Immune Biosolutions CEO Luc Paquet commented, “The COVID-19 pandemic has demonstrated how important it is to have the capacity to develop and, above all, produce our very own treatments to serve the Canadian population. Our goal is to be able to offer this treatment quickly to all Canadians who need it.”
Read the Immune Biosolutions press release.
